Developer docs
API playgroundTry for free, no card

Search company profiles

Tonic Bioventures

Full company profile

uuid0007qnf

Namestring
Tonic Bioventures
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Tonic Bioventures is an early-stage venture capital fund founded in 2020 and headquartered in Glen Burnie, Maryland, that invests across life sciences sub-sectors including therapeutics, diagnostics, and devices. The firm is led by two co-founders, Regina Leung and Jim Sergi, who both serve as general partners, suggesting a partnership-driven model typical of boutique specialist funds. Public information is sparse: the firm's own website returned a CAPTCHA/verification page rather than substantive content during data aggregation, and the only disclosed capital event surfaced is a 2022 funding round listing ExCapsa Group as an investor with a $0 disclosed value.

The firm's business model follows conventional venture fund economics: capital is raised from limited partners, deployed into early-stage life sciences companies, and the firm earns revenue through management fees (typically a percentage of committed capital) and carried interest on successful exits. With 11-50 employees, the organization is sized for a small specialist fund rather than a scaled multi-strategy platform. No portfolio companies, AUM figures, fund vintages, or LP roster are disclosed in the available data, which limits assessment of fund maturity, deployment pace, and underlying revenue drivers.

Short descriptiontext

Tonic Bioventures is an early-stage venture capital fund founded in 2020 and based in Glen Burnie, Maryland, that invests in life sciences companies across therapeutics, diagnostics, and devices. The firm is led by co-founders and general partners Regina Leung and Jim Sergi.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGlen Burnie, United States
HQ citystring
Glen Burnie
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital, life sciences investing, early-stage funding, therapeutics investment, biotech venture fund
Industry1 code
PRIMARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital (Life Sciences)
Social media profiles1 record
Cost components3 values
Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tonic Bioventures is an early-stage venture fund that invests in life sciences companies across therapeutics, diagnostics, and medical devices. The firm deploys capital into founding-stage and early-stage life sciences startups, supporting entrepreneurs developing new treatments, diagnostic tools, and device technologies.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Early-stage life sciences venture fund
CategoryVenture capital investing
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

ARCH is one of the largest and most established early-stage life-sciences venture firms, investing across therapeutics, diagnostics, and medical devices from seed through Series A — directly comparable in mandate and stage focus to Tonic Bioventures.

TypeDirect peer
Description

Atlas Venture is a dedicated early-stage life-sciences fund that builds biotech companies from inception, with a focus on therapeutics. Its early-stage, biotech-only mandate closely mirrors Tonic's stated focus on therapeutics, diagnostics, and devices.

TypeDirect peer
Description

5AM Ventures is an early-stage life-sciences investor focused on creating and building therapeutics and platform companies. Its stage focus and sector concentration make it a strong direct comparable to Tonic Bioventures.

TypeDirect peer
Description

Versant is a healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics at the early and growth stages, with a portfolio approach very similar to Tonic's stated investment scope.

TypeDirect peer
Description

Frazier Life Sciences invests exclusively in therapeutics and related life-sciences companies across all stages, including seed and Series A, making it a direct sector and stage comparable to Tonic Bioventures.

TypeDirect peer
Description

Lux Capital invests across frontier science and technology, with a substantial allocation to life sciences including therapeutics, diagnostics, and bio-platform companies, overlapping meaningfully with Tonic's investment scope.

TypeDirect peer
Description

Section 32 is a venture fund founded by a former Google Ventures general partner that invests in biotech, healthcare, and techbio at early stages. Its life-sciences orientation and early-stage mandate align with Tonic's focus.

TypeBroad incumbent
Description

NEA is a large, multi-stage venture firm with a significant life-sciences practice that invests across therapeutics, diagnostics, and devices. As a much larger incumbent, it is a relevant broad comparable but operates at materially different scale than Tonic.

TypeBroad incumbent
Description

Flagship Pioneering is a large bioplatform venture firm that creates and funds therapeutics and platform biotech companies. As a much larger and better-known incumbent, it is a relevant broad sector comparable to Tonic's therapeutics and diagnostics focus.

TypeBroad incumbent
Description

Andreessen Horowitz's Bio fund invests across therapeutics, diagnostics, and digital health at the early stages. As a well-capitalized incumbent with a dedicated life-sciences practice, it competes for the same early-stage deal flow as Tonic Bioventures.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tonic Bioventures

Venture Capital (Life Sciences)tonicbioventures.com

Tonic Bioventures is an early-stage venture capital fund founded in 2020 and based in Glen Burnie, Maryland, that invests in life sciences companies across therapeutics, diagnostics, and devices. The firm is led by co-founders and general partners Regina Leung and Jim Sergi.

What Tonic Bioventures does

Tonic Bioventures is an early-stage venture capital fund founded in 2020 and headquartered in Glen Burnie, Maryland, that invests across life sciences sub-sectors including therapeutics, diagnostics, and devices. The firm is led by two co-founders, Regina Leung and Jim Sergi, who both serve as general partners, suggesting a partnership-driven model typical of boutique specialist funds. Public information is sparse: the firm's own website returned a CAPTCHA/verification page rather than substantive content during data aggregation, and the only disclosed capital event surfaced is a 2022 funding round listing ExCapsa Group as an investor with a $0 disclosed value.

The firm's business model follows conventional venture fund economics: capital is raised from limited partners, deployed into early-stage life sciences companies, and the firm earns revenue through management fees (typically a percentage of committed capital) and carried interest on successful exits. With 11-50 employees, the organization is sized for a small specialist fund rather than a scaled multi-strategy platform. No portfolio companies, AUM figures, fund vintages, or LP roster are disclosed in the available data, which limits assessment of fund maturity, deployment pace, and underlying revenue drivers.

Tonic Bioventures firmographics

Firmographics
Name
Tonic Bioventures
Website
https://tonicbioventures.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Tonic Bioventures is an early-stage venture capital fund founded in 2020 and based in Glen Burnie, Maryland, that invests in life sciences companies across therapeutics, diagnostics, and devices. The firm is led by co-founders and general partners Regina Leung and Jim Sergi.
Ownership category
akta.pro rank

Tonic Bioventures industry classification

Industry
Product category
Venture Capital (Life Sciences)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAA
Early-Stage Venture Capital (Pre-Seed/Seed)

Keywords

  • Venture capital
  • Life sciences investing
  • Early-stage funding
  • Therapeutics investment
  • Biotech venture fund

Where Tonic Bioventures is headquartered

Location

Headquarters

HQ city
Glen Burnie
HQ country
United States
HQ region
North America

Markets served

Tonic Bioventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales

Tonic Bioventures product offering

Product offering

Core offering

Tonic Bioventures is an early-stage venture fund that invests in life sciences companies across therapeutics, diagnostics, and medical devices. The firm deploys capital into founding-stage and early-stage life sciences startups, supporting entrepreneurs developing new treatments, diagnostic tools, and device technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-stage life sciences venture fund

Companies that use Tonic Bioventures

Customer profile

Ideal customer profiles1 record

Tonic Bioventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tonic Bioventures partnerships and signals

Strategic signal

Recent moves2 records

Tonic Bioventures competitors and assessment

Company assessment

Direct peers

  • ARCH Venture Partners: ARCH is one of the largest and most established early-stage life-sciences venture firms, investing across therapeutics, diagnostics, and medical devices from seed through Series A — directly comparable in mandate and stage focus to Tonic Bioventures.
  • Atlas Venture: Atlas Venture is a dedicated early-stage life-sciences fund that builds biotech companies from inception, with a focus on therapeutics. Its early-stage, biotech-only mandate closely mirrors Tonic's stated focus on therapeutics, diagnostics, and devices.
  • 5AM Ventures: 5AM Ventures is an early-stage life-sciences investor focused on creating and building therapeutics and platform companies. Its stage focus and sector concentration make it a strong direct comparable to Tonic Bioventures.
  • Versant Ventures: Versant is a healthcare-focused venture firm investing across therapeutics, medical devices, and diagnostics at the early and growth stages, with a portfolio approach very similar to Tonic's stated investment scope.
  • Frazier Life Sciences: Frazier Life Sciences invests exclusively in therapeutics and related life-sciences companies across all stages, including seed and Series A, making it a direct sector and stage comparable to Tonic Bioventures.
  • Lux Capital: Lux Capital invests across frontier science and technology, with a substantial allocation to life sciences including therapeutics, diagnostics, and bio-platform companies, overlapping meaningfully with Tonic's investment scope.
  • Section 32: Section 32 is a venture fund founded by a former Google Ventures general partner that invests in biotech, healthcare, and techbio at early stages. Its life-sciences orientation and early-stage mandate align with Tonic's focus.

Broad incumbents

  • New Enterprise Associates (NEA): NEA is a large, multi-stage venture firm with a significant life-sciences practice that invests across therapeutics, diagnostics, and devices. As a much larger incumbent, it is a relevant broad comparable but operates at materially different scale than Tonic.
  • Flagship Pioneering: Flagship Pioneering is a large bioplatform venture firm that creates and funds therapeutics and platform biotech companies. As a much larger and better-known incumbent, it is a relevant broad sector comparable to Tonic's therapeutics and diagnostics focus.
  • Andreessen Horowitz Bio: Andreessen Horowitz's Bio fund invests across therapeutics, diagnostics, and digital health at the early stages. As a well-capitalized incumbent with a dedicated life-sciences practice, it competes for the same early-stage deal flow as Tonic Bioventures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Tonic Bioventures social profiles

Digital presence

Tonic Bioventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tonic Bioventures leadership team

Management profile

Number of profiles

Profiles2 records

Tonic Bioventures funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tonic Bioventures M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tonic Bioventures

What does Tonic Bioventures do?

Tonic Bioventures is an early-stage venture fund that invests in life sciences companies across therapeutics, diagnostics, and medical devices. The firm deploys capital into founding-stage and early-stage life sciences startups, supporting entrepreneurs developing new treatments, diagnostic tools, and device technologies.

When was Tonic Bioventures founded?

Tonic Bioventures was founded in 2020. It employs 1 to 10 people.

Where is Tonic Bioventures based?

Tonic Bioventures is headquartered in Glen Burnie, United States, in the North America region.

Who are Tonic Bioventures's main competitors?

Direct peers on record are ARCH Venture Partners, Atlas Venture, 5AM Ventures, Versant Ventures, Frazier Life Sciences, Lux Capital and Section 32. Broad incumbents are New Enterprise Associates (NEA), Flagship Pioneering and Andreessen Horowitz Bio.

Does Tonic Bioventures have an API?

No public API is recorded for Tonic Bioventures.

What industry is Tonic Bioventures in?

Tonic Bioventures's product category is Venture Capital (Life Sciences). Its primary akta.pro industry code is FSANAAAA, Early-Stage Venture Capital (Pre-Seed/Seed). Its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals